Vir Biotechnology swings to FY26 Q2 net income of $80.1 million; revenue rises to $238.9 million

PUBT · 1d ago
Vir Biotechnology swings to FY26 Q2 net income of $80.1 million; revenue rises to $238.9 million
  • Vir Biotechnology posted Q2 net income of USD 80.1 million, or USD 0.48 a share, swinging from a year-ago net loss.
  • Revenue rose to USD 238.9 million, driven by USD 238.9 million in license and collaboration revenue tied to Astellas upfront payment.
  • R&D expenses increased to USD 135.3 million from USD 97.5 million, due to a USD 48 million milestone payment to Sanofi.
  • Cash, cash equivalents and investments ended at about USD 1.01 billion, up about USD 198.5 million in the quarter.
  • Phase 3 ECLIPSE 1 topline data expected in Q4 2026; guidance sees cash funding operations into H2 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608051605BIZWIRE_USPR_____20260805_BW596908) on August 05, 2026, and is solely responsible for the information contained therein.